Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

923

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Neoplasms

Interventions

DRUG: Capivasertib
DRUG: Paclitaxel
DRUG: Placebo

Sponsor

AstraZeneca